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http:WHAT THIS PAPER ADDS
This study adds information regarding the effect of endovascular stenting of post-thrombotic patients with
iliofemoral obstruction. Using the Villalta score, it appears that only patients with severe post-thrombotic
syndrome beneﬁt from endovascular procedures, indicating that perhaps this should be used in the selection
criteria.Objective: The study aimed to evaluate the clinical results of stent placement in post-thrombotic patients with
iliofemoral obstruction compared with results in those treated with elastic compression stockings (ECS).
Methods: A retrospective analysis of post-thrombotic patients with iliofemoral obstruction was conducted in a
single institution from January 2007 to December 2012. Duplex ultrasound and selective phlebography were
performed in patients with chronic venous disease and previous deep venous thrombosis (DVT). Post-thrombotic
syndrome (PTS) with iliofemoral vein obstruction (Villalta score 10) was diagnosed in 216 patients. Among
these, 122 patients were treated by stent placement, and the remaining 94 patients were treated conservatively
with 30e40 mmHg ECS therapy. Technical success, stent patency rates, and complications were recorded after
the interventions. Results including Villalta score, pain, edema, ulcer, and popliteal vein reﬂux were assessed in
both groups.
Results: Percutaneous iliofemoral venous stenting was successful in 116 of 122 patients (95.1%) without major
complications. Follow up periods ranged from 3 to 58 months (median 21 months). Cumulative primary, assisted
primary, and secondary stent patency rates at 3 years were 68.9%, 79.0%, and 91.6%, respectively. Among
patients with severe PTS, the Villalta score decreased signiﬁcantly with endotreatment, compared to the score of
those treated by ECS therapy (16.12  4.91 vs. 10.98  5.89, p < .01). However, there was no signiﬁcant score
improvement between the two therapies in patients with moderate PTS (6.59  2.37 vs. 5.75  3.03, p ¼ .22).
There was a signiﬁcantly higher 24 month recurrence free ulcer healing rate in the endotreatment groups (86.6%
vs. 70.6%, p < .01). Both edema and pain improved signiﬁcantly in the two groups. The popliteal vein reﬂux rate
showed no signiﬁcant change after endotreatment.
Conclusions: Endovascular treatment is a safe, effective, and feasible method to correct the iliofemoral
obstruction of PTS. Only post-thrombotic patients with severe PTS as assessed by the Villalta score appear to
beneﬁt from the endovascular treatment.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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diseaseINTRODUCTION
The most frequent sequela that develops after deep venous
thrombosis (DVT) is post-thrombotic syndrome (PTS), and it
has a cumulative incidence of 20e50% within 2 years.1,2
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//dx.doi.org/10.1016/j.ejvs.2015.03.029heaviness, venous ectasia, edema, pain, hyperpigmentation,
and, in severe cases, leg ulceration.3,4 Despite anticoagulant
therapy for treatment of acute DVT, there is still a high
incidence of severe symptoms in patients with iliofemoral
PTS.5 Previously, the only surgical option in post-thrombotic
patients with iliofemoral obstruction, who failed conserva-
tive treatment was venous bypass; however, this is a chal-
lenging procedure with poor long-term graft patency.6
Considering the poor results of venous grafts, endovas-
cular treatment has been developed as an alternative in the
treatment of post-thrombotic patients with iliofemoral vein
obstruction.7 Initial studies on its use have recently
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clinical and stent outcomes, which indicate the value of
endovascular therapy in treating PTS with iliofemoral
obstruction.8e11 In 2014, a scientiﬁc statement from the
American Heart Association (AHA) mentioned that for
severely symptomatic patients with post-thrombotic occlu-
sion of their common femoral vein, iliac vein, and vena
cava, combined operative and endovenous disobliteration
may be considered.12
Most of the studies on stenting of PTS have shortcom-
ings, for example small number of patients with short-term
follow up and lack of control groups, such as compression
therapy and medication.13e15 Additionally, some of the
published experience predates the development of objec-
tive reporting standards for the diagnosis and outcome
assessment of PTS.12
The aim of this study was to assess the impact of
endovascular treatment on the severity of PTS with iliofe-
moral obstruction, the ulcer healing rate, lower limb
swelling and pain, as well as popliteal vein reﬂux when
present. Patients treated with stocking compression therapy
formed the control group.
METHODS
Study group
After obtaining institutional review board approval, a
retrospective review of the Shanghai Ninth People’s Hos-
pital database was completed between January 2007 and
December 2012. All patients with chronic venous disease
and previous DVT underwent duplex ultrasound (DUS). One
experienced vascular technician performed the DUS using a
Siemens ACUSON CV-70 scanner with a 3.5 or 5 MHz probe.
Iliac, femoral, popliteal, and deep calf veins were evaluated
in the longitudinal plane. The following criteria indicated
post-thrombotic disease: vessel wall abnormalities (wall
thickening, irregularities, reduced or occluded lumen) and
ﬂow in prominent collateral veins. Ascending phlebography
(the injection of contrast medium into a dorsal foot vein)
was selectively performed in patients whose iliac veins were
difﬁcult to visualize on DUS. To identify post-thrombotic
patients with iliofemoral obstruction, transfemoral/popli-
teal venography was performed in cases with either: (1)
visible pelvic collateral veins, ascending lumbar vein or
stenosis/occlusion of the iliofemoral vein on phlebography,
or (2) peak vein velocity ratio of >2.5 across the suspected
iliofemoral vein obstruction or absence of blood ﬂow on
DUS.
All patients suffering from PTS with iliofemoral obstruc-
tion (>50% stenosis or occlusion on venography) and
moderate/severe symptoms (Villalta score 10) were
included in the present study and advised to undergo
endovascular treatment. A proportion of patients declined
endovascular treatment because of concerns with potential
complications, while others could not afford the cost. In
these cases, thigh high 30e40 mmHg elastic compression
stockings (ECS) were applied for long-term treatment. These
patients formed the control group. Popliteal vein reﬂux wasalso recorded in the two groups. Reﬂux was deﬁned as ﬂow
retrograde to the direction of physiological ﬂow, lasting for
more than 0.5 seconds. Exclusion criteria included acute
DVT less than 6 months prior to treatment; prior DVT
thrombectomy or thrombolysis including failed stenting;
mild symptoms (Villalta score <10); the presence of ulcers
unrelated to venous disease; signiﬁcant obstruction (>50%
stenosis) of the femoral vein; post-thrombotic changes
associated with the inferior vena cava; bilateral iliofemoral
vein; popliteal vein and/or calf vein; as well as any con-
traindications to the use of ECS such as dermatitis or al-
lergy; and an ankle brachial index of <0.9.Procedure
Endovascular treatment was performed under local anes-
thesia. The common femoral vein was chosen as the
preferred access in patients with involvement of the iliac
vein only. In case of common femoral vein obstructive le-
sions, popliteal vein access was gained using the phlebog-
raphy roadmap or with ultrasound guidance. After sheath
insertion, a bolus of 80 U/kg of heparin was injected and
supplemented as required to maintain an activated clotting
time of >250 seconds. The technical details of cannulation
and recanalization of iliofemoral obstruction have been
outlined previously.16 In brief, after successful access and
heparinization, a straight 0.018 inch or 0.035 inch hydro-
philic guide wire was directed through the iliofemoral vein
obstruction under the guidance of a matched multipurpose
catheter or angled tip catheter. Sometimes a wire loop
technique was used to ﬁnd the path of least resistance.
Percutaneous transluminal angioplasty (PTA) was per-
formed after successful cannulation of the iliofemoral
lesion. Balloon catheters (EverCross; ev3 Endovascular, Inc.;
ReeKross; ClearStream Technologies, Wexford, Ireland;
PowerFlex P3; Cordis Corporation) with diameter of 4e
16 mm and length of 60e220 mm were used for dilation.
Elastic recoil after PTA was very common. As a result, self
expanding stents (EverFlex; ev3 Endovascular, Inc.; LIFE-
STENT; BARD, Tempe, Arizona; WALLSTENT; Boston Scien-
tiﬁc Corporation) with diameter of 10e16 mm and length of
60e150 mm were implanted to cover the entire lesion after
PTA. The common femoral vein stent was deployed, usually
below the inguinal ligament, to ensure adequate inﬂow in
patients with recoil after common femoral vein PTA. Post-
dilation was necessary because of the common phenome-
non of recoil after stenting. Antero-posterior and oblique
venography was performed after intervention to conﬁrm
the ﬁnal results and identify any complications. All patients
provided written informed consent before treatment.
The post-interventional treatment protocol included
administration of 4100 I.U AXa/0.4 mL nadroparin (Frax-
iparine, GlaxoSmithKline, Brentford, UK) every 12 hours
while an inpatient and oral anticoagulation with warfarin
(International Normalized Ratio of 2e3) for at least 6
months after discharge. No ECS was applied in the mod-
erate PTS group as most moderate patients improved
rapidly after stenting. Thigh high ECS (30e40 mmHg) were
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for 1e3 months, and prolonged ECS in cases with unhealed
ulcers after 3 months. All patients in the ECS group
continued to wear the stockings throughout the study
period. Pre-operative local ulcer care treatments were
continued after intervention until the ulcer had healed.
Deﬁnitions
A total Villalta score between 0 and 4 indicates no PTS,
while a score of 5 indicates PTS. Patients with a total score
of 5e9 are classiﬁed as mild PTS; those with a score of 10e
14 have moderate PTS. Patients with a score of 15 or a
venous ulcer are diagnosed with severe PTS.12,17 Technical
success was deﬁned as recanalization with antegrade ﬂow
and <30% residual stenosis after stent placement. Com-
plications were classiﬁed as major and minor based on the
Society of Interventional Radiology (SIR) standards.18 In-
stent re-stenosis was recorded as 50% stenosis, as
demonstrated on DUS, computed tomography (CT), or
phlebography. Primary patency was deﬁned as conﬁrmed
patency with <50% re-stenosis on follow up without any
repeat intervention. Assisted primary patency was achieved
via secondary endovascular interventions to treat 50% re-
stenosis involving the originally treated venous segment.
Secondary patency was deﬁned as patency in the target
lesion maintained by repeat intervention after occlusion of
the treated venous segment. The degree of pain was
assessed using a visual analog scale (VAS) ranging from 0 to
10. Limb edema was evaluated as none (0), evening edema
in the ankle only (1), afternoon edema above the ankle (2),
or morning edema above the ankle requiring activity change
(3). Ulcer healing was deﬁned by the presence of complete
epithelialization.
Follow up
Technical success rates and complications were recorded
after intervention. Both the endotreatment and ECS treat-
ment groups were followed up at 3, 6, and 12 months, and
then annually according to clinical results (pre- and post-
treatment Villalta scores, pain, edema, and the presence
of ulcer). Isolated popliteal vein reﬂux was evaluated at the
same follow up points. DUS was primarily used to evaluate
the patency of the stent. If in-stent re-stenosis/occlusion
was found along with recurrence of symptoms, phlebog-
raphy or CT was chosen to further conﬁrm the degree and
length of the re-stenosis/occlusion. Compliance of the use
of stockings, which was deﬁned as wearing ECS during daily
activity, was assessed by telephone follow up every 3
months.
Statistical analysis
Individual data were summarized using frequencies or
percentages for categorical factors, the median (range) for
continuous variables. SPSS version 13.0 (SPSS, Inc., Chicago,
IL, USA) was used for statistical analyses. Cumulative
patency rate and recurrence free ulcer healing rate were
calculated with Kaplan-Meier. The risk factors of primarypatency loss were evaluated through univariate and multi-
variate analyses using a Cox proportional hazards regression
model. ANOVA was used to compare clinical results
regarding Villalta score, pain, and edema. The popliteal vein
reﬂux rate was tested using a Fisher exact test. A p value of
<.05 was considered signiﬁcant.
RESULTS
Patient characteristics
This retrospective study comprised 216 patients (128
women) with 216 limbs (181 left limbs). One hundred and
twenty-two patients were treated by endovascular inter-
vention and the remaining 94 patients were treated
conservatively with 30e40 mmHg ECS therapy. The median
age, female to male ratio, and left to right ratio did not
differ between the endotreatment group and the ECS
group. No difference was observed in either the time from
onset of DVT or the ratio of previous use of ECS 2 years
between the two groups (Table 1).
The clinical presentation of both groups spanned the
spectrum of CEAP clinical classiﬁcation. There were more C3
patients and less C5 patients in the endotreatment group
(27.0% vs. 14.9%, p ¼ .045 and 4.9% vs. 13.8% p ¼ .029).
Obstruction involving the common femoral vein was found
in 17.2% of the endotreatment group and 11.7% of the ECS
group, respectively (p ¼ .335). The rate of associated
popliteal vein reﬂux between the two groups also showed
no signiﬁcant differences (54.9% vs. 59.6%, p ¼ .579)
(Table 2). No difference was observed in the Villalta score
between the two groups (Table 4).Technical success and complications
The overall technical success rate was 95.1% (116 of 122
patients). All of the technical failures (six patients) were
caused by inability to cross the occluded venous lesions. The
median duration of the procedure was 55 minutes (range
10e130 minutes). A median of three balloons (range 2e5)
and two stents (range 1e3) were used per procedure.
Stents were successfully deployed in 19 patients with
involvement of part of the common femoral vein, including
two occlusive and 17 stenosis lesions.
All patients tolerated the procedure well and no major
complications, such as puncture site hematoma/bleeding,
pulmonary embolism, or peri-operative deaths, were
encountered. Minor complications occurred in 73 patients
(59.8%), including lower back pain after stent deployment in
59 patients (48.4%) and wire induced venous perforation in
32 patients (26.2%). Lower back pain was usually self
limiting and relieved 1e3 days after the procedure and
without medication. All venous perforations resolved after
withdrawal of the wire and short-term observation. There
was no delayed hemorrhage reported after stent placement.Stent patency rate
The median follow up period was 21 months (range 3e58
months). One-hundred and two patients (87.9%) were
Table 1. Demographic characteristics of the patients.
Variable Data p
Endovascular treatment Compression therapy
No. of limbs 122 94
Median age, years (range) 46 (30e81) 42 (28e76) .619
Women vs. men 75:47 53:41 .487
Left vs. right 103:19 78:16 .853
Median time from onset of DVT, years (range) 9 (0.5e40) 7.5 (1e35) .775
Previous use of ECS 2 years (%) 15 (12.3) 9 (9.6) .528
Previous PE (%) 13 (10.7) 7 (7.4) .484
Cancer history (%) 11 (9.0) 13 (13.8) .282
Inherited or acquired thrombophilia (%) 6 (4.9) 8 (8.5) .216
Chronic renal insufﬁciency (%) 4 (3.3) 5 (5.3) .507
Coronary artery disease (%) 12 (9.8) 14 (14.9) .295
Diabetes mellitus (%) 19 (15.6) 13 (13.8) .847
Hyperlipidemia (%) 13 (10.7) 17 (18.1) .164
Hypertension (%) 15 (12.3) 9 (9.6) .663
Obesity (BMI >32 kg/m2) (%) 19 (15.6) 21 (22.3) .220
DVT ¼ deep venous thrombosis; ECS ¼ elastic compression stockings; PE ¼ pulmonary embolism; BMI ¼ body mass index (weight [kg]/
height2 [m2]).
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primary, assisted primary, and secondary patency rates at
36 months were 68.9%, 79.0%, and 91.6% respectively
(Fig. 1). Re-stenosis or occlusion of the treated lesions
occurred in 24 patients, including nine stents below the
inguinal ligament. The cumulative primary patency rates at
12 months of patients with and without common femoral
vein stents were 59.2% and 89.1%, respectively. One of two
occlusions (50%) and nine of 17 stenoses (52.9%) in the
common femoral vein were still patent after stenting. No
stent fracture was found. Common femoral vein stent was
the only risk factor for primary loss of patency (hazard
ratio ¼ 2.18, p ¼ .024) (Table 3). Among the re-stenosis/
occlusion cases, seven patients declined repeatTable 2. CEAP characteristics of the patients.
CEAP variable Data p
Endovascular
treatment
Compression
therapy
No. of limbs 122 94
Clinical classiﬁcation
C1 (%) 0 (0) 0 (0)
C2 (%) 4 (3.3) 8 (8.5) .134
C3 (%) 33 (27.0) 14 (14.9) .045
C4 (%) 30 (24.6) 18 (19.1) .410
C5 (%) 6 (4.9) 13 (13.8) .029
C6 (%) 49 (40.2) 41 (43.6) .677
Etiology
Secondary (%) 122 (100) 94 (100)
Anatomic lesions
Iliac vein (%) 101 (82.8) 83 (88.3) .335
Iliac-femoral vein (%) 21 (17.2) 11 (11.7) .335
Pathophysiologic classiﬁcation
Obstruction (%) 55 (45.1) 38 (40.4) .579
Reﬂux (popliteal) and
obstruction (%)
67 (54.9) 56 (59.6) .579
Occlusion (%) 102 (83.6) 61 (64.9) .002
CEAP ¼ Clinical Etiology Anatomy Pathophysiology.intervention and opted for compression treatment, identi-
ﬁed as loss of patency in the endovascular treatment group.
Repeat endovascular treatment was successfully performed
in the remaining 17 patients, including angioplasty in 13
cases, thrombolysis with angioplasty for underlying occlu-
sions in three cases, and angioplasty with stent placement
in one case.Clinical results
Eight patients (8.5%) were unable to comply with the ECS
treatment after 3e18 months of follow up. There was sig-
niﬁcant decrease of the Villalta score in both groups after
treatment. However, a signiﬁcantly greater decrease in
score was observed only in the severe Villalta score groupFigure 1. Cumulative primary, assisted primary, and secondary
patency rates of iliofemoral stent placement. The lower numbers
represent limbs at risk for each time interval (SEM was <10% at
point before 42 months).
Table 3. The risk factors of primary patency loss.
Variables Univariate Multivariate
HR (95% CI) p HR (95% CI) p
Male 1.37 (0.51e2.13) .084 1.24 (0.22e2.01) .107
Age >60 years 0.81 (0.37e4.37) .273 1.14 (0.45e4.41) .421
Left limb 0.58 (0.16e3.12) .391 0.77 (0.23e3.46) .312
Thrombophilia 1.35 (0.46e2.78) .062 0.86 (0.29e3.12) .113
Cancer history 0.73 (0.26e2.45) .165 0.89 (0.44e2.51) .187
Occlusion 2.63 (0.95e5.17) .078 2.89 (0.92e6.08) .082
No. of stents >1 1.53 (0.28e1.89) .432 0.87 (0.41e1.45) .411
Common femoral vein stent 2.33 (1.68e3.42) .017 2.18 (1.51e3.34) .024
Venous perforation 0.76 (0.34e1.49) .283 0.89 (0.47e1.59) .316
Endo-procedure >60 minutes 0.73 (0.14e1.87) .069 1.15 (1.79e1.90) .132
Severe Villalta score 1.96 (0.79e3.68) .246 2.21 (0.96e4.21) .167
HR ¼ hazard ratio; CI ¼ conﬁdence interval.
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15e24 vs. median 12, range 9e20, p < .01) (Table 4).
Active ulcers were present before treatment in 49 pa-
tients in the endotreatment group and in 41 patients in the
ECS group. There was a signiﬁcantly higher 24 month
recurrence free ulcer healing rate in the endotreatment
groups (86.6% vs. 70.6%, p < .01). Both edema and pain
improved signiﬁcantly in the two groups after the corre-
sponding treatment (Table 5). The popliteal vein reﬂux rate
showed no signiﬁcant change after treatment in both the
endotreatment and ECS groups (54.9% vs. 46.3%, p ¼ .192;
59.6% vs. 50.6%, p ¼ .227).DISCUSSION
Despite being a retrospective study, the patient de-
mographics between the two groups were similar. However,
using the CEAP classiﬁcation, the endovascular group had a
higher proportion of C3 and a lower proportion of C5 pa-
tients, although the proportion of lower limbs with active
ulcers (C6) showed no signiﬁcant difference. The endovas-
cular group had a signiﬁcantly higher rate of post-
thrombotic occlusion of the iliofemoral veins compared
with the ECS group. Although the Villalta score improved inTable 4. Villalta scores before and after treatment.
Variable
Villalta score before treatment Moderate PTS
Severe PTS
Moderate þ severe PTS
Villalta score after treatment Moderate PTS
Severe PTS
Moderate þ severe PTS
Villalta score change between before
and after treatment
Moderate PTS
Severe PTS
Moderate þ severe PTS
PTS ¼ post-thrombotic syndrome.
a p < .01, compared with the corresponding Villalta score before treathe groups with moderate and severe PTS regardless of the
type of treatment, the endovascular treatment was superior
to the ECS treatment in patients with severe PTS. The
recurrence free ulcer healing rate and the improvement of
pain were also superior in the endovascular group of pa-
tients. The improvement of swelling was similar in both
groups.
Since the initial report in the mid-1990s, the concept of
endovascular treatment of iliac vein obstructive disease has
become more popular.12,19 Recently, several papers have
shown the efﬁciency of the endovascular technique in
treatment of iliocaval obstructive disease.8e11,13e15 How-
ever, some studies mix patients with different underlying
etiologies including primary (May-Thurner syndrome) and
secondary (post-thrombotic syndrome) disease.9,10,20,21 In
reports focusing on post-thrombotic patients, the technical
success rate ranged from 85% to 93%.12,19 The largest, most
carefully studied cohort of patients was reported in the
study by Neglén et al., which showed the results of endo-
vascular treatment of 464 PTS lesions followed for more
than 6 years post-operatively. The primary, assisted primary,
and secondary cumulative patency rates were 57%, 80%,
and 86%, respectively.9 The results of the present study
conﬁrmed the high technical success and promising mid-Data p
Endovascular treatment,
median (range)
Compression therapy,
median (range)
13 (11e14) 13 (10e14) .301
27 (15e33) 25 (15e32) .168
22 (11e33) 20 (10e32) .274
7 (2e13)a 6 (3e11)a .814
9 (7e18)a 13 (8e24)a <.01
8 (2e18)a 11 (3e24)a <.01
7 (2e10) 6 (3e9) .22
17 (15e24) 12 (9e20) <.01
13 (2e24) 9 (3e20) <.01
tment.
Table 5. The edema and pain score of before and after treatment.
Variable Data p
Endovascular treatment,
median (range)
Compression therapy,
median (range)
Edema score before treatment Moderate PTS 3 (0e3) 3 (0e3) .957
Severe PTS 3 (1e3) 3 (1e3) .056
Moderate þ severe PTS 3 (0e3) 3 (0e3) .212
Edema score after treatment Moderate PTS 1 (0e3)a 1 (0e3)a .612
Severe PTS 1 (0e3)a 1 (0e3)a .052
Moderate þ severe PTS 1 (0e3)a 1 (0e3)a .070
Pain score before treatment Moderate PTS 5 (1e7) 5 (0e7) .147
Severe PTS 8 (4e9) 7 (4e9) .667
Moderate þ severe PTS 7 (1e9) 6.5 (0e9) .130
Pain score after treatment Moderate PTS 2 (0e5)a 2 (0e6)a .498
Severe PTS 4 (1e6)a 5 (2e7)a <.01
Moderate þ severe PTS 3 (0e6)a 4 (0e7)a .007
The degree of post-thrombotic syndrome (PTS) assessed by the Villalta score.
a p < .01, compared with the corresponding score before treatment.
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the safety of stent placement for iliofemoral obstructive
PTS. As previously reported, stents extending below the
inguinal ligament are the major risk factors for in-stent re-
stenosis in patients with PTS.16 This corresponds to the
ﬁndings in this study and is contrary to Neglén et al., who
emphasized that patency rates relied on the underlying
etiology and the need for recanalization and not on the
extension of the stent below the inguinal ligament.7 That
study however included patients with both non-thrombotic
and post-thrombotic obstructions.
Because of the wide spectrum of symptoms and dynamic
changes over time, the diagnostic criteria and clinical eval-
uation of PTS are controversial. A number of clinical tools or
scales have been used to help deﬁne PTS, mainly including
the CEAP (clinical, etiological, anatomic, pathophysiological)
classiﬁcation, VCSS (Venous Clinical Severity Score), and
Villalta score.3,12 Bond et al. reviewed the surgical results of
PTS in 2012.Ten of 12 studies reported CEAP classiﬁcation
and one assessed VCSS, but Villalta score was not used in
these studies.22 Given its minor diagnostic and symptom
assessment value, as well as the absence of PTS speciﬁc
ﬁndings in CEAP and VCSS, the American Heart Association
has recently recommended the use of the Villalta score for
PTS diagnosis and severity classiﬁcation.12 Using the Villalta
score in this study, it was found that the differences in the
clinical results of endotreatment compared with ECS varied
among patients with different degrees of PTS. Although
there was signiﬁcant clinical improvement in the endo-
treatment group of patients with moderate and severe PTS,
only patients with severe PTS were statistically better
comparing the endovenous treatment and ECS groups. Pa-
tients with a severe PTS by the Villalta score appear to do
better having iliofemoral stent placement.
PTS covers a wide range of symptoms and differs from
patient to patient, with typical symptoms of lower limb PTSincluding pain, edema, and ulcer (a sign of advanced dis-
ease).3,7,12 In this study, both endotreatment and ECS
showed signiﬁcant therapeutic effects in terms of relief
from pain, edema, and ulcer. However, there was a statis-
tically higher recurrence free ulcer healing rate in the
endotreatment group than in the ECS group and the pain
relief was more substantial in the stented group with severe
PTS. According to the deﬁnition of the Villalta score, pa-
tients presenting with venous ulcer were classiﬁed as se-
vere PTS regardless of the Villalta score.12 Based on this
reason, the higher ulcer healing rate in the endotreatment
group may partially explain the signiﬁcant therapeutic effect
of endotreatment among the severe PTS patients. In addi-
tion, most patients would consider not using a stocking as a
beneﬁt of a treatment, especially when thigh high stockings
were needed. Endovenous stenting made it possible to
abandon the use of stockings for patients with moderate
PTS and patients with severe PTS after 1e3 months if the
leg ulcer had healed.
Although almost 50% of the post endotreatment patients
presented with popliteal venous reﬂux without correction,
the symptoms were greatly improved only with iliofemoral
disobliteration. The present study further conﬁrmed the
report by Raju et al., which revealed that iliac venous
stenting alone signiﬁcantly improved the clinical outcome in
patients with combined iliofemoral outﬂow obstruction and
deep venous reﬂux, even though the deep reﬂux compo-
nent was left uncorrected.23
The study has several limitations. The most importance is
the single center retrospective design and the uncertainty
of whether or not the ECS and endotreatment groups are
comparable as discussed above. Other weaknesses include
lack of analysis of hemodynamic changes such as air
plethysmography, pressure measurement, complete map-
ping of the reﬂux in the lower limb, absence of quality of
life instrument, and short follow up period (median 21
Clinical Assessment of Endovenous Stenting 107months). Long-term follow up is essential for the endo-
treatment of PTS as stent patency and late ulcer recurrence
are well described. Future studies, particularly prospective
randomized clinical trials will be needed to conﬁrm the
signiﬁcant beneﬁts of endotreatment for severe iliofemoral
obstructive PTS.
In conclusion, the present results suggest that endovas-
cular treatment is a safe, effective, and feasible method for
the correction of patients with PTS and iliofemoral ob-
structions. Patients with severe PTS (as diagnosed with the
Villalta score) might beneﬁt more from the stent placement.
ECS therapy shows equal clinical effects with stent place-
ment in patients with moderate PTS. The stented patients
did, however, not have to wear any stockings after the
procedure.
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